Lamm W, Kaufmann H, Raderer M, Hoffmann M, Chott A, Zielinski C, Drach J. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica [Internet]. 2011Jun.30 [cited 2026Nov.1];96(7):1008-14. Available from: https://haematologica.org/article/view/6008